Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Y-axis displays relative risk on the log scale, X-axis displays all the prescribed drugs studied grouped by the anatomical therapeutic chemical (ATC) classification.Relative risks (95% CIs) of pulmonary embolism within 30 days after the drug was dispensed, selected by BOLASSO approach in both countries.Type of drugATC codeDrug namesSwedenNorwayTotal (Norway and Sweden pooled)RR (95% CI)RR (95% CI)RR (95% CI)Proton pump inhibitorsA02BC02Pantoprazole1.44 (1.21 to 1.72)1.68 (1.24 to 2.27)1.50 (1.29 to 1.74)Antiemetics and antinauseantsA04AA01Ondansetron0.78 (0.61 to 1.01)0.94 (0.77 to 1.14)0.87 (0.73 to 1.04)Drugs for treating constipationA06AB08Sodium picosulfate0.68 (0.47 to 0.98)0.98 (0.85 to 1.11)0.85 (0.60 to 1.21)A06AD11Lactulose1.52 (1.07 to 2.15)1.08 (0.96 to 1.22)1.23 (0.89 to 1.70)AntibioticsA07AA02Nystatin1.82 (1.18 to 2.80)1.94 (1.55 to 2.44)1.91 (1.57 to 2.34)AntipropulsivesA07DA03Loperamide1.42 (0.95 to 2.10)1.08 (0.89 to 1.31)1.17 (0.92 to 1.49)Anti-diabetic drugA10BA02Metformin0.79 (0.59 to 1.06)0.96 (0.82 to 1.11)0.91 (0.76 to 1.08)Mineral supplementsA12AXCalcium, combinations with vitamin D and/or other drugs0.95 (0.78 to 1.16)0.87 (0.78 to 0.96)0.89 (0.81 to 0.97)A12BA01Potassium chloride1.29 (0.88 to 1.89)1.08 (0.92 to 1.28)1.11 (0.95 to 1.29)AntithromboticsB01AB04Dalteparin2.15 (1.63 to 2.84)2.40 (2.05 to 2.80)2.34 (2.04 to 2.68)B01AB05Enoxaparin2.56 (1.86 to 3.53)1.37 (1.05 to 1.80)1.86 (1.01 to 3.43)B01AC04Clopidogrel1.61 (1.07 to 2.43)1.40 (1.14 to 1.72)1.44 (1.20 to 1.73)Antianemic drugB03AA01Ferrous glycine sulfate2.26 (0.75 to 6.79)1.34 (0.88 to 2.03)1.43 (0.97 to 2.12)VasodilatorsC01DA02Glyceryl trinitrate1.73 (1.31 to 2.28)1.28 (1.12 to 1.46)1.45 (1.08 to 1.94)DiureticsC03AB01Bendroflumethiazide and potassium0.78 (0.52 to 1.16)0.44 (0.23 to 0.85)0.62 (0.36 to 1.08)C03CA01Furosemide1.48 (1.26 to 1.74)1.27 (1.17 to 1.36)1.35 (1.16 to 1.56)C03EA01Hydrochlorothiazide and potassium-sparing agents0.79 (0.53 to 1.17)0.83 (0.72 to 0.97)0.83 (0.72 to 0.95)Anti-varicose drugsC05BA01Organo-heparinoid2.02 (1.20 to 3.42)2.00 (1.63 to 2.45)2.00 (1.66 to 2.42)Beta-blockersC07AG02Carvedilol0.48 (0.29 to 0.79)0.62 (0.39 to 0.99)0.55 (0.39 to 0.78)Angiotension II receptor blockers (ARBs)C09CA06Candesartan0.89 (0.69 to 1.16)0.98 (0.85 to 1.12)0.96 (0.85 to 1.08)C09DA06Candesartan and diuretics0.78 (0.56 to 1.08)0.78 (0.61 to 1.02)0.78 (0.64 to 0.96)Lipid-lowering agentsC10AA01Simvastatin0.87 (0.75 to 1.01)0.87 (0.79 to 0.95)0.87 (0.80 to 0.94)C10AA03Pravastatin0.64 (0.40 to 1.03)0.64 (0.41 to 1.00)0.64 (0.46 to 0.89)Corticosteroids for systemic useH02AB06Prednisolone1.04 (0.91 to 1.20)1.12 (1.02 to 1.23)1.09 (1.01 to 1.18)Anti-thyroid drugsH03AA01Levothyroxine sodium0.99 (0.82 to 1.20)0.87 (0.79 to 0.97)0.90 (0.81 to 1.02)AntibioticsJ01AA02Doxycycline2.84 (2.32 to 3.47)2.75 (2.47 to 3.07)2.77 (2.52 to 3.05)J01CA04Amoxicillin2.69 (2.20 to 3.28)2.51 (2.14 to 2.95)2.58 (2.28 to 2.92)J01CA08Pivmecillinam1.48 (1.19 to 1.82)1.43 (1.21 to 1.67)1.45 (1.27 to 1.65)J01CE02Phenoxymethylpenicillin3.31 (2.81 to 3.89)2.82 (2.51 to 3.16)3.02 (2.59 to 3.53)J01EA01Trimethoprim1.30 (0.94 to 1.79)1.35 (1.07 to 1.70)1.33 (1.10 to 1.61)J01EE01Sulfamethoxazole and trimethoprim2.22 (1.50 to 3.29)1.73 (1.34 to 2.23)1.87 (1.49 to 2.35)J01FA01Erythromycin3.29 (2.41 to 4.49)2.17 (1.52 to 3.09)2.70 (1.79 to 4.05)J01MA02Ciprofloxacin2.11 (1.63 to 2.75)1.90 (1.66 to 2.17)1.94 (1.72 to 2.19)J01XE01Nitrofurantoin2.76 (1.74 to 4.39)1.41 (1.14 to 1.73)1.91 (0.99 to 3.67)Antineoplastic and immunomodulating agentsL03AA13Pegfilgrastim (immunostimulant)1.76 (0.91 to 3.43)2.18 (0.80 to 5.95)1.88 (1.08 to 3.27)L04AX03Methotrexate (immunosuppresant)0.58 (0.35 to 0.98)0.64 (0.48 to 0.84)0.63 (0.49 to 0.80)Anti-inflammatory and antirheumaticsM01AB05Diclofenac1.40 (1.18 to 1.65)1.07 (0.97 to 1.19)1.21 (0.93 to 1.58)M01AE01Ibuprofen0.79 (0.61 to 1.02)0.92 (0.77 to 1.11)0.87 (0.75 to 1.02)OpioidsN02AA01Morphine2.45 (1.40 to 4.26)1.78 (1.50 to 2.11)1.86 (1.50 to 2.32)N02AA05Oxycodone1.59 (1.19 to 2.12)1.80 (1.58 to 2.05)1.76 (1.57 to 1.99)N02AA55Oxycodone and naloxone2.28 (1.04 to 5.01)1.78 (1.07 to 2.96)1.92 (1.25 to 2.94)N02AA59Codeine, combinations excl. psycholeptics1.80 (1.57 to 2.07)1.29 (1.14 to 1.45)1.52 (1.10 to 2.11)N02AB03Fentanyl1.81 (1.08 to 3.03)1.59 (1.21 to 2.08)1.64 (1.29 to 2.08)N02AE01Buprenorphine1.37 (0.90 to 2.08)1.38 (1.06 to 1.80)1.38 (1.10 to 1.72)N02AX02Tramadol1.88 (1.55 to 2.27)1.16 (1.05 to 1.29)1.47 (0.91 to 2.35)AnalgesicsN02BE01Paracetamol1.17 (1.02 to 1.33)1.19 (1.13 to 1.27)1.19 (1.13 to 1.25)AnxiolyticsN05BA01Diazepam1.06 (0.86 to 1.30)1.12 (0.93 to 1.34)1.09 (0.95 to 1.25)N05BA04Oxazepam1.26 (1.02 to 1.55)1.19 (1.06 to 1.33)1.21 (1.09 to 1.33)Hypnotics and sedativesN05CD02Nitrazepam0.84 (0.58 to 1.20)0.75 (0.50 to 1.10)0.80 (0.61 to 1.04)N05CF01Zopiclone1.02 (0.91 to 1.16)1.16 (1.06 to 1.28)1.09 (0.97 to 1.24)N05CF02Zolpidem1.25 (0.88 to 1.78)1.05 (0.94 to 1.18)1.07 (0.96 to 1.19)AntidepressantsN06AB10Escitalopram1.10 (0.87 to 1.39)1.16 (0.88 to 1.54)1.12 (0.94 to 1.35)N06AX11Mirtazapine1.42 (1.00 to 2.02)1.47 (1.26 to 1.72)1.46 (1.27 to 1.69)AntiprotozoalsP01AB01Metronidazole1.39 (0.96 to 2.02)1.78 (1.37 to 2.32)1.63 (1.29 to 2.06)Drugs for obstructive airway diseaseR03AC02Salbutamol1.50 (1.21 to 1.87)1.44 (1.19 to 1.74)1.47 (1.27 to 1.69)R03AK07Formoterol and budesonide1.21 (0.90 to 1.62)1.14 (1.00 to 1.31)1.15 (1.02 to 1.30)Drugs for cough and cold preparationsR05CB01Acetylcysteine1.12 (0.91 to 1.37)1.12 (1.00 to 1.25)1.12 (1.00 to 1.25)R05FA02Opium derivatives and expectorants2.01 (1.14 to 3.55)1.73 (1.53 to 1.95)1.74 (1.55 to 1.96)Other opthalmologicalsS01XA20Artificial tears and other indifferent preparations0.49 (0.32 to 0.77)0.89 (0.74 to 1.06)0.68 (0.38 to 1.22)ATC code anatomical therapeutic chemical (ATC), 5th level.
Source: Results. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Review / evidence synthesis.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Meta-analysis reported · Blinding not applicable to this review · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Separate analyses were conducted for the Norwegian and Swedish data and we present both country-specific and combined estimates, using meta-analysis to combine the country-specific estimates.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Dispensed prescription medications and short-term risk of pulmonary embolism in Norway and Sweden
Review / evidence synthesis · Scientific Reports · 2024
Original publication title
Dispensed prescription medications and short-term risk of pulmonary embolism in Norway and Sweden
© The Author(s) 2024
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
Scandinavian electronic health-care registers provide a unique setting to investigate potential unidentified side effects of drugs. We analysed the association between prescription drugs dispensed in Norway and Sweden and the short-term risk of developing pulmonary embolism. A total of 12,104 pulmonary embolism cases were identified from patient: and cause-of-death registries in Norway (2004 to 2014) and 36,088 in Sweden (2005 to 2014). A case-crossover design was used to compare individual drugs dispensed 1 to 30 days before the date of pulmonary embolism diagnosis with dispensation in a 61 to 90 day time-window, while controlling for the receipt of other drugs.
A BOLASSO approach was used to select drugs that were associated with short-term risk of pulmonary embolism. Thirty-eight drugs were associated with pulmonary embolism in the combined analysis of the Norwegian and Swedish data. Drugs associated with increased risk of pulmonary embolism included certain proton-pump inhibitors, antibiotics, antithrombotics, vasodilators, furosemide, anti-varicose medications, corticosteroids, immunostimulants (pegfilgrastim), opioids, analgesics, anxiolytics, antidepressants, antiprotozoals, and drugs for cough and colds. Mineral supplements, hydrochlorothiazide and potassium-sparing agents, beta-blockers, angiotensin 2 receptor blockers, statins, and methotrexate were associated with lower risk.
Most associations persisted, and several additional drugs were associated, with pulmonary embolism when using a longer time window of 90 days instead of 30 days. These results provide exploratory, pharmacopeia-wide evidence of medications that may increase or decrease the risk of pulmonary embolism. Some of these findings were expected based on the drugs' indications, while others are novel and require further study as potentially modifiable precipitants of pulmonary embolism.
Authors’ abstract
Scandinavian electronic health-care registers provide a unique setting to investigate potential unidentified side effects of drugs. We analysed the association between prescription drugs dispensed in Norway and Sweden and the short-term risk of developing pulmonary embolism. A total of 12,104 pulmonary embolism cases were identified from patient: and cause-of-death registries in Norway (2004 to 2014) and 36,088 in Sweden (2005 to 2014). A case-crossover design was used to compare individual drugs dispensed 1 to 30 days before the date of pulmonary embolism diagnosis with dispensation in a 61 to 90 day time-window, while controlling for the receipt of other drugs.
A BOLASSO approach was used to select drugs that were associated with short-term risk of pulmonary embolism. Thirty-eight drugs were associated with pulmonary embolism in the combined analysis of the Norwegian and Swedish data. Drugs associated with increased risk of pulmonary embolism included certain proton-pump inhibitors, antibiotics, antithrombotics, vasodilators, furosemide, anti-varicose medications, corticosteroids, immunostimulants (pegfilgrastim), opioids, analgesics, anxiolytics, antidepressants, antiprotozoals, and drugs for cough and colds. Mineral supplements, hydrochlorothiazide and potassium-sparing agents, beta-blockers, angiotensin 2 receptor blockers, statins, and methotrexate were associated with lower risk.
Most associations persisted, and several additional drugs were associated, with pulmonary embolism when using a longer time window of 90 days instead of 30 days. These results provide exploratory, pharmacopeia-wide evidence of medications that may increase or decrease the risk of pulmonary embolism. Some of these findings were expected based on the drugs' indications, while others are novel and require further study as potentially modifiable precipitants of pulmonary embolism.
Publication and source details
Original title: Dispensed prescription medications and short-term risk of pulmonary embolism in Norway and Sweden
Dagfinn Aune; Ioannis Vardaxis; Bo Henry Lindqvist; Ben Michael Brumpton; Linn Beate Strand; Jens Wilhelm Horn; Inger Johanne Bakken; Pål Richard Romundstad; Kenneth J. Mukamal; Rickard Ljung; Imre Janszky; Abhijit Sen
Scientific Reports · 2024
© The Author(s) 20242024https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Central Norway Regional Authorityproject number 46060913Janszky ImreRepository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T09:40:59.036446+00:00
DOI: 10.1038/s41598-024-69637-4 · PMC11362151